Passions

IPOs

Literature

Gator football

Experience

ACELYRIN Announces Pricing of Upsized Initial Public Offering

May 15, 2023

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Read more

Related contacts

Chadwick Mills
Partner, San Francisco
Charlie Kim
Partner, San Diego
Anitha Anne
Associate, San Francisco
Barbara Mirza
Partner, Los Angeles Santa Monica
Alexander Lee
Partner, Los Angeles Santa Monica
Joshua Mates
Partner, San Francisco
Phil Mitchell
Partner, New York
Brad Goldberg
Partner, New York
Peter Adams
Partner, San Diego
Lauren Creel
Partner, Palo Alto
Koji Fukumura
Partner, San Diego
Patrick Gibbs
Partner, Palo Alto
David Peinsipp
Partner, San Francisco
Barbara Borden
Partner, San Diego
David Navetta
Partner, Colorado
Patrick Van Eecke
Partner, Brussels
Shannon Eagan
Partner in Charge – Palo Alto, Palo Alto
Darren DeStefano
Partner, Reston
Francis Wheeler
Partner, Colorado
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington DC
Brett White
Of Counsel, Palo Alto
Dani Nazemian
Special Counsel, San Diego
Jennifer Shanley
Special Counsel, New York
Jacquelyn Burke
Special Counsel, Boston
Karen Tsai
Special Counsel, Washington DC
Miriam Petrillo
Special Counsel, Chicago
Andrew Nelms
Associate, San Francisco
Amy Mao
Associate, San Francisco
David D. Kim
Associate, San Francisco
Lawrence Traylor
Associate, Los Angeles Santa Monica
Dionne A. Thomas
Associate, San Diego
Nathaniel Hearn Jr.
Associate, New York
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Eileen Leman
Associate, Los Angeles Downtown
Kelly McCormick
Associate, San Francisco
Mor Agam
Associate, New York
Allison Kutner
Associate, New York
Madison (JJ) Meng
Associate, San Francisco
Rebecca Siegel
Associate, San Francisco
Rachel F. Katz
Associate, New York
Mari Dugas
Associate, Washington DC
Loriane Sangaré-Vayssac
Associate, Brussels
Megan Drill
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Kristin R. Marshall
Associate, Washington DC
John T. Stellini
Associate, Palo Alto
Luke X. Blackett
Associate, San Francisco

LumiraDx Limited – $100.3 Million Follow-on Offering and Concurrent Private Placement

August 24, 2022

Cooley advised the underwriters in LumiraDx Limited’s $100.3 million aggregate financing, consisting of (1) a $75.3 million follow-on offering of 43,000,000 shares of common stock at a public offering price of $1.75 per share and (2) a $25.0 million concurrent private placement with the Bill & Melinda Gates Foundation. LumiraDx is a diagnostics company manufacturing and commercializing an innovative diagnostic platform that supports a broad menu of tests with lab-comparable performance at the point of care. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Jesse Schulman
Associate, Washington DC
Mike Lam
Associate, Los Angeles Santa Monica

Arcutis Biotherapeutics – $172.5 Million Follow-on Offering

August 24, 2022

Cooley advised the underwriters in Arcutis Biotherapeutics’ $172.5 million follow-on offering of 8,625,000 shares of common stock at a public offering price of $20.00 per share. Arcutis is a biopharmaceutical company developing and commercializing innovative treatments for immuno-dermatological diseases. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Christine Turner
Associate, Colorado
Madison (JJ) Meng
Associate, San Francisco
Mike Lam
Associate, Los Angeles Santa Monica
Lawrence Traylor
Associate, Los Angeles Santa Monica
Kate Walther
Paralegal Specialist, San Diego

Pliant Therapeutics – $230.0 Million Follow-on Offering

August 24, 2022

Cooley advised the underwriters in Pliant Therapeutics’ $230.0 million follow-on offering of 12,432,432 shares of common stock at a public offering price of $18.50 per share. Pliant is a clinical-stage biotechnology company discovering and developing novel therapies for the treatment of fibrosis. Partners Denny Won, Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
David Peinsipp
Partner, San Francisco
Valerie Sapozhnikova
Associate, Los Angeles Downtown
Madison (JJ) Meng
Associate, San Francisco
Marjorie Roesser
Associate, San Francisco

Zymeworks – $115 Million Follow-On Offering

June 2, 2022

Cooley advised the underwriters on Zymeworks’ $115.0 million follow-on public offering of 11,035,000 common shares at a price to the public of $8.00 per share and pre-funded warrants to purchase 3,340,000 common shares at a price to the public of $7.9999 per pre-funded warrant. This includes 1,875,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. Zymeworks is a clinical-stage biopharmaceutical company developing and commercializing of next-generation multifunctional biotherapeutics. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Brett White
Of Counsel, Palo Alto
Madison (JJ) Meng
Associate, San Francisco
Ron Metzger
Paralegal Specialist, San Francisco
Kris Tsao Cachia
Paralegal Specialist, San Francisco
View more

Rankings & accolades

Daily Journal: California Lawyer Attorneys of the Year Awards (2020); Top 100 Lawyers in California (2019 – 2020); Top 20 Under 40 (2014)

Chambers USA: Capital Markets: Debt & Equity – California & Nationwide (Western United States) (2019 – 2022)

IFLR1000 US: Lawyer of the Year – Capital Markets (2020)

Law 360: Capital Markets MVP (2019)

Legal 500: Leading Lawyer - Capital Markets: Equity Offerings (2020 – 2022); Next Generation Lawyer - Capital Markets: Equity (2019)

Memberships & affiliations

American Bar Association

The Bar Association of San Francisco

Representative issuers:

Dave has represented companies/investment banks on capital market transactions involving issuers across industries, such as: 10X Genomics, 4D Molecular Therapeutics, Accelerate Diagnostics, Acutus Medical, Aerohive Networks, Alteryx, ALX Oncology, Ambarella, Amyris, Applied Molecular Transport, Anthera Pharmaceuticals, Apigee, Applied Molecular Transport, Annexon, Apptio, Arcadia Biosciences, Arcutis Biotherapeutics, Aridis Pharmaceuticals, ARMO BioSciences, Ascendis Pharma, ASLAN Pharmaceuticals, Atlassian, Athira Pharma, Audentes Therapeutics, Cision, Crinetics Pharmaceuticals, Dermira, DocuSign, Doximity, Dutch Bros., EHang, Eidos Therapeutics, Expensify, Fantex, FIGS, FireEye, Five Prime Therapeutics, Global Blood Therapeutics, Gossamer Bio, Graphite Bio, Gritstone Oncology, Guardant Health, Health Catalyst, HealthEquity, Hyperion Therapeutics, IGM Biosciences, Ignyta, Immune Design, Inhibrx, Invitae, Kinnate Biopharma, Kodiak Sciences, LinkedIn, Livongo Health, Lulu’s Fashion Lounge, Lyell Immunopharma, MINDBODY, Mobile Iron, NantKwest, Nanthealth, NerdWallet, New Relic, Olema Pharmaceuticals, Ooma, Opendoor Labs, Otonomy, Pliant Therapeutics, Principia Biopharma, PROCEPT BioRobotics, ProNai, ProQR Therapeutics, PROS Holdings, Rigel Pharmaceuticals, Qualtrics, Root, Sana Biotechnology, Satsuma Pharmaceuticals, Savara, Shockwave Medical, Sierra Oncology, Smart Share Global, Snap, Stitch Fix, Sutro Biopharma, Sweetgreen, Syndax Pharmaceuticals, Tableau Software, Taiwan Liposome Company, Treace Medical Concepts, Tricida, Trivascular, Twilio, Uber, Ventyx, ViewRay, Warby Parker, Wish, Xenon Pharmaceuticals, Xometry, Yelp, Zendesk, Zscaler, Zymeworks, Zynga.